Tonix Pharmaceuticals (TNXP) announced a collaboration with Massachusetts General Hospital, MGH, a founding member of Mass General Brigham, MGB, to conduct a Phase 2 clinical trial evaluating monoclonal antibody TNX-1500 in kidney transplant recipients. The investigator-initiated study will be led by Ayman Al Jurdi, M.D., at MGH and is designed to assess the safety, tolerability and activity of Fc-modified anti-CD40L mAb TNX-1500 in preventing kidney transplant rejection while significantly minimizing the dose of conventional immunosuppressive drugs, which are associated with infection, cancer, cardiovascular side effects and various metabolic derangements. The CD40 ligand is also known as CD154. Study initiation is contingent on institutional review board approval and FDA clearance of an investigator-initiated investigational new drug application, IND.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
- Tonix Pharmaceuticals presents data on Tonmya at ACR Convergence
- Tonix Pharma Begins FOCUS Study on AVP-D Treatment
- Tonix Pharmaceuticals announces first patient dosed in FOCUS study at MGH
- Tonix Pharmaceuticals presents data on TNX-801 Mpox vaccine
- Tonix presents update on TNX-1500 at Japan Society for Transplantation